BPC-1 is under clinical development by Meabco and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BPC-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BPC-1 is under development for the treatment of metastatic breast cancer, pancreatic cancer and Burkitt Lymphoma. The therapeutic candidate is administered intramuscularly. BP-C1 (combination of BP-Cx-1 and platinum) is a benzene-poly-carboxylic acid, cis-diammineplatinum (II) dichloride complex. It acts by targeting DNA. It was also under development for the treatment of lymphoma and other solid tumors including bladder, prostate, colon, and head & neck cancers.
Meabco is a pharmaceutical company that develops drugs for cancer and radiation induced injuries. The company developed product candidates based on its patented technology that comprise BP-C1 and BP-C2 that possess immunomodulating properties. Its BP-C1 helps to treat a variety of cancers with its apoptotic and anti-proliferative properties and is used both as monotherapy and in combinations with other cancer drugs. Meabco’s BP-C2 drug candidate improves the hematopoietic system and protects the gastrointestinal system and helps in their recovery following damage induced by radiation, disease and chemical agents. The company collaborates with the institutions and scientists to enhance its research and development. Meabco is headquartered in Copenhagen, Denmark.
For a complete picture of BPC-1’s drug-specific PTSR and LoA scores, buy the report here.